This inventor holds 5 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent. Top assignees: Intralytix, Inc., Surmodics, Inc.. Active years: 2004-2011.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2004-2011
Zemphira Alavidze is an innovative inventor and researcher based in Tbilisi, Georgia. He has made significant contributions through his numerous patents, with a total of 4 patents to his name. One of his notable inventions is a pharmaceutical composition containing bacteriophage, which is aimed at reducing the risk of bacterial infection or sepsis in susceptible patients.
The method described in Alavidze's patents involves treating vulnerable patients with bacteriophage compositions, specifically targeting pathogenic bacteria that are susceptible to the bacteriophage's lytic infections. By administering this pharmaceutical composition, the goal is to decrease the level of pathogenic bacteria colonization in the patient by at least one log. This approach is particularly beneficial for immunocompromised patients such as leukemia, lymphoma, carcinoma, sarcoma, allogeneic transplant, congenital or acquired immunodeficiency, cystic fibrosis, and AIDS patients.
These inventions have the potential to revolutionize the field of healthcare and provide improved treatment options for preventing bacterial infections in susceptible individuals. The innovative work done by Zemphira Alavidze highlights the importance of exploring alternative solutions to combat antibiotic-resistant bacteria and improve patient outcomes.
Zemphira Alavidze is associated with the company INTRALYTIX, INC., which focuses on the development and commercialization of bacteriophage-based products. Working alongside esteemed coworkers such as J Glenn Morris and Alexander Sulakvelidze, Alavidze and his team at INTRALYTIX, INC. are at the forefront of groundbreaking research and innovation in bacteriophage therapies.
Overall, Zemphira Alavidze's patents and work in the field of bacteriophage compositions demonstrate a commendable commitment to advancing healthcare and reducing the risk of bacterial infections in vulnerable patients. His inventions contribute to the growing body of knowledge in the field, bringing us closer to more effective and personalized treatments for infectious diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile